http://rdf.ncbi.nlm.nih.gov/pubchem/patent/NO-317063-B1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d53094985a54e1cafd22f23d76be4007 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-575 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-575 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-00 |
| filingDate | 1998-05-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2f2e6468e3b7218a7dda9c64a0fab717 |
| publicationDate | 2004-08-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | NO-317063-B1 |
| titleOfInvention | Use of UDCA (ursodeoxycholic acid) for the prevention and treatment of liver disease in mammals |
| abstract | One aspect of the invention is directed to a pharmacologically acceptable composition comprising a sulfate of 3α, 7β-dihydroxy-5β-cholan-24-oic acid (ursodeoxycholic acid or "UDCA") and a pharmaceutically acceptable carrier. In a preferred composition, the sulfate is UDCA-3-sulfate, UDCA-7-sulfate, UDCA-3,7-disulfate, glyco-UDCA-3-sulfate, glyco-UDCA-7-sulfate, glyco-UDCA-3,7- disulfate, tauro-UDCA-3-sulfate, tauro-UDCA-7-sulfate, tauro-UDCA-3,7-disulfate or a combination thereof. A second spectrum is a method of administering UDCA to a mammal to inhibit or treat a disorder which comprises administering a sulfate of UDCA to the mammal in an amount sufficient to inhibit or treat the disorder. For example, a UDCA sulfate may be used to the benefit of inhibiting or treating an inflammatory condition of the gastrointestinal tract, such as colon cancer, rectal cancer, a neoplasm of the colon, a neoplasm of the rectum, carcinogenesis of the colon, carcinogenesis of the rectum, ulcerative colitis. an adenomatous polyp, familial polyposis. A sulfate of UDCA may also be administered to inhibit or treat an inflammatory disorder of the liver. A UDCA sulfate can be used to improve serum biochemistry in the liver in case of disease or liver disease or to increase bile flow or to reduce biliary secretion of phospholipid or cholesterol. According to a further aspect, the invention is directed to a method of maintaining an isolated organ by perfusing the organ with a sulfate of UDCA. |
| priorityDate | 1995-11-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 32.